A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer

Publication date: Available online 28 August 2022Source: Biochemical PharmacologyAuthor(s): L. Wester, S. Venneker, M. Hazenoot, C. Pont, E. Koedoot, A.M. Timmermans, J. Martens, M.P.H.M. Jansen, C.E.M. Kockx, W.F.J. van Ijcken, J.H.N. Meerman, Y. Zhan…